Abstract 439P
Background
Ewing’s sarcoma and osteosarcoma have high incidence in teenage and young adults (TYA) with age range(15-29 years). This study investigated the epidemiology of cancers among TYA population,with a special emphasis on Ewing’s sarcoma, evaluating theimpact of symptom delay and system delay variables on the patient outcomes.
Methods
This was a single-center, retrospective cross-sectional study conducted between June 2015 and March 2020 on TYA patients with a confirmed diagnosis of cancer. TYA patients registered with Ewing’s sarcoma were selected for the study using a non-probability sampling technique. The symptom delay was defined as >1 month duration from the first symptom to the consultation by primary care physician (PCP). The system delay was defined as >1 month duration from initial consultation by PCP to referring the patient to a dedicated cancer center.
Results
Our study gives a comprehensive overview of cancer epidemiology among TYA patients. Our observation is that 7.35% (450/6120) of our cancer patients are TYAs. Ewing’s sarcoma was found in 8.88% (40/450) of all the TYA cancer patients.Symptom delay was noted among 65.0% of patients and system delay occurred among 57.5% of patients. We observed that symptom delay and system delay at presentation had a significant impact on the patient outcome in terms of increased metastasis and reduced progression free survival. Patients with large tumor volume (>100 cc) had poor Progression Free Survival (PFS), showing a strong negative correlation between tumor volume and PFS. Mean five-year PFS for patients with no detectable metastatic disease at diagnosis was significantly better than for those with metastases (59m vs. 19m, respectively; P<.001). Table: 439P
Correlation of PFS with clinical variables
Parameter | Variable | n | PFS (months) Mean ±SD | p-value | ||
Localized Disease | No | 15 | 18.93±8.74 | p<0.001 | ||
Yes | 25 | 59.28±16.09 | ||||
Symptom Delay in Survived | No | 14 | 69.07±10.12 | p<0.001 | ||
Yes | 16 | 40.69±15.19 | ||||
System Delay in Survived | No | 16 | 66.94±12.20 | p<0.001 | ||
Yes | 14 | 39.07±14.62 |
Conclusions
Ewing’s sarcoma should be considered the prototype of a TYA cancer. Efforts in improving access to healthcare facilities, education of primary healthcare physicians, pediatricians and orthopedic surgeons is of paramount importance to facilitate an early diagnosis and establish care pathways.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
YO11 - Satisfactory response after Rituximab-Bendamustin in Poor Performance Status Geriatric with Relapsed DLBCL
Presenter: Yasjudan Putra
Session: Poster viewing 06
YO12 - Allogeneic hematopoietic stem cell transplant in a case of acute myeloid leukaemia with end stage renal disease
Presenter: DEVYANI SURANGE
Session: Poster viewing 06
YO13 - Rosai-Dorfman Disease Presenting with Multiple Contiguous Lymphadenopathy: A Case Report
Presenter: Lean Marx Maaño
Session: Poster viewing 06
YO15 - Nasopharyngeal carcinoma in pregnancy: A Case Report
Presenter: Mary Antonette Ong
Session: Poster viewing 06
YO16 - New onset SIADH masquerading progression in esthesioneuroblastoma
Presenter: Muthu Manikandan
Session: Poster viewing 06
YO17 - Olfactory Neuroblastoma with Cervical Lymph Node Metastases in a 21- Year old Filipino Woman: A Case Report
Presenter: Mary Antonette Ong
Session: Poster viewing 06
YO18 - Challenges in Provision of Patient centered care with a Practical approach in a Resource-limited setting - Steven Johnson Syndrome – Toxic Epidermal Necrolysis (SJS-TEN) overlap related to Phenytoin use and review of logistical challenges related to care provision - a Case Report.
Presenter: Rahul D. Arora
Session: Poster viewing 06
YO19 - Posterior Reversible Encephalopathy Syndrome associated with Pharmacological management of Bowel obstruction at the end of life – a review of two cases separated by 5 years
Presenter: Rahul D. Arora
Session: Poster viewing 06
YO20 - A case of drug-induced large vessel vasculitis with hoarseness as the chief complaint caused by pegfilgrastim during chemotherapy
Presenter: Takuya Sato
Session: Poster viewing 06
YO23 - Neo-adjuvant immunotherapy in operable non-small cell lung carcinoma
Presenter: Padmini S N
Session: Poster viewing 06